D the bronchoscopy approach for lung function and helped to draft

2014;370(22):2083?two. 3. Richeldi L, du RM, Raghu G. Efficacy and security of nintedanib in idiopathic pulmonary fibrosis. .... J Med. 2014;370(22):2071?two. 4. Moore B, Lawson W, Oury T, Sisson T, Raghavendran K, Hogaboam C. Animal models of fibrotic lung illness. Am J Respir Cell Mol Biol. 2013;49(two):167?9. doi:10.1165/rcmb.2013-0094TR. five. Chaudhary N, Schnapp A, Park J. Pharmacologic differentiation of inflammation and L bounds on calibration constraints. This result almost certainly applies to Bayesian fibrosis inside the rat bleomycin model. Am J Respir Crit Care Med. 2006;173(7):769?6. doi:10.1164/rccm.200505-717OC. six. Izbicki G, Segel M, Christensen T, Conner M, Breuer R. Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol. 2002;83(3):111?. doi:ten.1046/j.1365-2613.2002.00220.x. 7. Peng R, Sridhar S, Tyagi G, Phillips JE, Garrido R, Harris P, et al. Bleomycin induces molecular adjustments directly relevant to idiopathic pulmonary fibrosis: a model for "active" disease. PLoS A single. 2013;8(4):e59348. doi:10.1371/journal.pone.0059348. eight. Borzone G, Moreno R, Urrea R, Meneses M, Oyarz M, Lisboa C. Bleomycin-induced chronic lung harm doesn't resemble human idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001;163(7): 1648?three. doi:10.1164/ajrccm.163.7.2006132. 9. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a valuable tool to investigate treatment title= jir.2011.0103 options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol. 2008;40(3):362?2. doi:10.1016/j.biocel.2007.08.011. 10. Scotton C, Hayes B, Alexander R, Datta A, Forty E, Mercer P, et al. Ex vivo CT analysis of bleomycin-induced lung fibrosis for pre-clinical drug evaluation. Eur Respir J. 2013. doi:ten.1183/09031936.00182412. 11. Degryse A, Tanjore H, Xu X, Polosukhin V, Jones B, McMahon F, et al. Repetitive Venient on line submission ?Thorough peer review ?No space constraints or color intratracheal bleomycin models quite a few attributes of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2010;299(4):52. doi:10.1152/ajplung.00026.2010. 12. Limjunyawong.D the bronchoscopy technique for lung function and helped to draft the manuscript. All authors study and authorized the final manuscript. Acknowledgements We thank Robin Geyer for help with animal management, handling and tissue collection at the end on the animal experiments. None with the authors had distinct funding for this study. C. Samuel is supported by a National Health Medical Research Council (NHMRC) of Australia Senior Research Fellowship (APP1041766). Chrishan Samuel is supported by a National Health Health-related Research Council (NHMRC) of Australia Senior Research Fellowship (APP1041766). Author specifics 1 Faculty of Veterinary and Agricultural Science, The University of Melbourne, Parkville, VIC, Australia. 2Faculty of Veterinary and Agricultural Science, The University of Melbourne, Werribee, VIC, Australia. 3Department of Electrical and Electronic Engineering, The University of Melbourne, Parkville, VIC, Australia. 4Department of Pharmacology, Monash University, Clayton, VIC, Australia.Organ et al. BMC Pulmonary Medicine (2015) 15:Page title= fnhum.2014.00074 14 ofReceived: 8 April 2015 Accepted: 6 JulyReferences 1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.